



# JEVITY® 1.5 CAL is now covered



Now listed on the RGAM,\*  
JEVITY 1.5 CAL has exception drug status,  
which is covered for reimbursement.

## High-calorie formula with fibre & prebiotics

The prebiotics in Jevity 1.5 Cal are short-chain FOS (fructo-oligosaccharides), added at levels shown to support the growth of bifidobacteria in the colon,<sup>1-3</sup> to help create an environment unfavourable to “harmful” bacteria, such as *C. difficile*.<sup>3,4†</sup>

- Tube or oral-feeding



† in vitro data

For use under medical supervision

\* Régime général d'assurance médicaments



# JEVITY 1.5 CAL is now covered

## Reimbursable indications for Jevity 1.5 CAL include:<sup>5</sup>

- Enteral feeding
- Total liquid nutrition for those requiring nutritional formulas due to oesophageal dysfunction, dysphagia, digestive problems, or malabsorption
- For children suffering from malnutrition, malabsorption, or failure-to-thrive, due to a medical condition
- For people with cystic fibrosis



## Jevity 1.5 CAL

Nutrition Information	235 mL	1000 mL	1500 mL
<b>Calories</b>	<b>355</b>	<b>1500</b>	<b>2250</b>
<b>Protein, g</b>	<b>15.0</b>	<b>63.8</b>	<b>95.7</b>
<b>Total Carbohydrate, g</b>	<b>50.7</b>	<b>215.7</b>	<b>323.6</b>
<b>Dietary Fibre, g</b>	<b>2.8</b>	<b>12</b>	<b>18</b>
<b>FOS, g</b>	<b>2.4</b>	<b>10</b>	<b>15</b>
<b>Fat, g</b>	<b>11.7</b>	<b>49.8</b>	<b>74.7</b>

### References

1. Bouhnik Y *et al.* The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double blind, randomized, placebo-controlled, parallel-group, dose response relation study. *Am J Clin Nutr* 2004;80:1658-64.
2. Bouhnik Y, Vahedi K, Achour L *et al.* Short-chain fructo-oligosaccharide administration dose-dependently increases bifidobacteria in healthy humans. *J Nutr* 1999;129:113-6.
3. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. *J Nutr* 1995;125:1401-12.
4. Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against *Clostridium difficile* in vitro. *Appl Environ Microbiol* 2003 April;69(4):1920-7.
5. Liste de médicaments du régime général, February 1<sup>st</sup>, 2008.